



## MEDICAL TIPS

**DIABIZ TABLET**

*Issue XI, No. 41, 2022*

### **Dapagliflozin Reduces Uric Acid Concentration, an Independent Predictor of Adverse Outcomes in DAPA-HF**

McDowell K *et.al. Eur J Heart Fail.* 2022; 24(6):1066-1076.

- Uric acid (UA) levels are frequently elevated in patients with heart failure and reduced ejection fraction (HFrEF).
- Reduction in UA is desirable in HFrEF and sodium-glucose cotransporter 2 inhibitors may have this effect; this was analyzed in the present study.
- Compared with placebo, Dapagliflozin reduced UA by 0.84 mg/dL ( $p < 0.001$ ) over 12 months and improved outcomes.
- The finding that Dapagliflozin lowered UA in patients with HFrEF is important because hyperuricemia is common in this population

**Dapagliflozin is associated with reduced UA and improved outcomes in patients with HFrEF**

